Related Experiment Video
Updated: Jun 20, 2025
11:09
High-Resolution Cardiac Positron Emission Tomography/Computed Tomography for Small Animals
Published on: December 16, 2022
3.7K
Nonfungible Tokens in Cardiovascular Medicine
Solomon Bendayan1, Yossi Cohen1, Joshua Bendayan1
1Faculty of Medicine, McGill University, Montreal, Quebec, Canada.
The Canadian Journal of Cardiology
|July 20, 2024
Summary
Nonfungible tokens (NFTs) enhance health data security and patient control in cardiovascular medicine. NFTs enable secure data sharing and empower patients in managing their health information and research participation.
Area of Science:
- Biomedical informatics
- Blockchain technology
- Cardiovascular medicine
Background:
- Electronic health records (EHRs) face challenges in security and interoperability.
- Patient data is often siloed across various healthcare providers and devices.
- Decentralized systems offer potential solutions for data management and ownership.
Purpose of the Study:
- To explore the integration of nonfungible tokens (NFTs) in healthcare, specifically cardiovascular medicine.
- To examine how NFTs can enhance the security, interconnection, and patient-centricity of electronic health data.
- To outline use-cases and identify key players in the emerging field of NFTs for cardiovascular care.
Main Methods:
- Review of current literature and emerging applications of NFTs in healthcare.
- Analysis of blockchain technology and smart contracts for data security and access control.
- Identification of potential use-cases in patient-centered cardiovascular medicine.
Main Results:
- NFTs can serve as unique digital certificates, binding health data to patients on a blockchain.
- Smart contracts can delineate access rights for providers and researchers, ensuring data security and immutability.
- Patients gain enhanced control over their data, incentivizing active health monitoring and participation in research.
Conclusions:
- NFTs offer a disruptive shift towards secure, interconnected, and patient-centered electronic health data management.
- Potential exists for NFTs to revolutionize cardiovascular care by empowering patients and streamlining data access.
- Further research and development are needed to address ethical and technical limitations for widespread adoption.
Related Concept Videos
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
2.2K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.2K
01:22Heart Failure Drugs: β-Blockers
336
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
336
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
133
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
133
01:16Antianginal Drugs: Nitrates and β-Blockers
571
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
571
01:22Heart Failure Drugs: Diuretics
361
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
361